CellBion Co., Ltd. (KOSDAQ:308430)
South Korea · Delayed Price · Currency is KRW 25,250
-250 (-0.98%)
At close: Feb 6, 2026
CellBion Revenue
CellBion had revenue of 679.12M KRW in the quarter ending September 30, 2025, a decrease of -42.34%. This brings the company's revenue in the last twelve months to 2.13B, down -2.44% year-over-year. In the year 2024, CellBion had annual revenue of 2.29B with 55.64% growth.
Revenue (ttm)
2.13B
Revenue Growth
-2.44%
P/S Ratio
152.12
Revenue / Employee
n/a
Employees
n/a
Market Cap
324.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.29B | 818.55M | 55.64% |
| Dec 31, 2023 | 1.47B | -291.63M | -16.54% |
| Dec 31, 2022 | 1.76B | 846.00M | 92.27% |
| Dec 31, 2021 | 916.88M | -443.71M | -32.61% |
| Dec 31, 2020 | 1.36B | 1.01B | 288.80% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 385.76B |
| Kyung Dong Pharmaceutical | 193.64B |
| GREEN CROSS WellBeing | 151.06B |
| DAE HWA Pharmaceutical | 149.47B |
| High Tech Pharm | 75.60B |
| Vivozon Pharmaceutical | 66.40B |
| Organoidsciences | 2.55B |
| ImmuneOncia Therapeutics | 715.75M |